Anesthesia & Analgesia· 2026Q1· Review
Effects of Ketamine and Esketamine on Postoperative Delirium After General Anesthesia: A Meta-Analysis and Meta-Regression Analysis
- 0citations
- Q1SCImago
- 2026year
Short summary
Perioperative ketamine (RR 0.69) and esketamine (RR 0.58) reduced postoperative delirium (POD) incidence in 3344 patients across 25 RCTs, particularly with higher doses and in major surgery, though trial sequential analysis found evidence inconclusive.
AI-generated from the title and abstract; the full text is not read.
Key points
- Ketamine (RR 0.69) and esketamine (RR 0.58) reduced POD incidence in 3344 patients across 25 RCTs.
- Benefits were greater with high-dose regimens (>0.5 mg/kg ketamine or >0.25 mg/kg esketamine) and bolus-plus-infusion strategies.
- The effect was observed when POD was assessed 2-7 days postoperatively, not within 24 hours.
- Dizziness risk increased (RR 1.45), while postoperative depressive symptoms decreased (RR 0.78).
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: Postoperative delirium (POD) is a frequent and serious complication, particularly in older adults undergoing major surgery. Pharmacologic prevention remains limited. This study aimed to evaluate whether perioperative ketamine or esketamine reduces POD incidence and to explore optimal administration strategies. METHODS: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to January 2025 for randomized controlled trials (RCTs) comparing perioperative ketamine or esketamine with placebo or standard care. The primary outcome was POD incidence (risk ratio [RR]). Subgroup, meta‑regression, and trial sequential analysis (TSA) were performed. Sensitivity analyses addressed active comparators and unit‑of‑analysis issues. RESULTS: Twenty-five RCTs (3344 patients) were included (ketamine: 9; esketamine: 16). Both agents reduced POD risk versus control (ketamine: RR 0.69, 95% CI, 0.49–0.98, P = .04; esketamine: RR 0.58, 95% CI, 0.36–0.95, P = .03). Benefit was more evident with high-dose regimens (single bolus: ketamine >0.5 mg/kg or esketamine >0.25 mg/kg; cumulative dose: ketamine >1.0 mg/kg or esketamine >0.5 mg/kg), bolus-plus-infusion, and in major surgery. The effect was observed when POD was assessed 2 to 7 days postoperatively, but not within 24 hours. TSA indicated that current evidence remains inconclusive due to insufficient information size. Dizziness risk increased (RR 1.45, 95% CI, 1.14–1.84, P = .002), while postoperative depressive symptoms decreased (RR 0.78, 95% CI, 0.63–0.96, P = .02; based on 2 studies, 493 patients). CONCLUSIONS: Perioperative ketamine and esketamine show a potential signal for POD reduction, particularly with optimized dosing in high‑risk patients. However, the evidence is currently inconclusive, and increased dizziness risk precludes routine recommendation. Large, multicenter RCTs are urgently needed.
The authors' abstract, as published at the source. Anesthesia & Analgesia, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Critical Care and Intensive Care Medicine
Critical Care and Intensive Care MedicineMedicine